You are here:
Direct Healthcare Professional Communication (DHPC) on Lojuxta® (Lomitapide): liver function monitoring and contraindication during pregnancy
2021.02.17
Active substance: lomitapide
Amryt Pharmaceuticals DAC in agreement with the European Medicines Agency (EMA) and the Federal Institute for Drugs and Medical Devices (BfArM) would like to remind you that Lomitapide is contraindicated in patients with moderate or severe hepatic impairment and those with unexplained persistent abnormal liver function tests as well as during pregnancy. Liver function should be monitored before and during treatment with lomitapide (see table included in the DHPC for specific recommendations).
Download DHPC / Information letter , Download_VeroeffentlichtAm_EN